ArticleBiochemistry. Biokhimiia2022
Trends in Human Species-Specific Lifespan and Actuarial Aging Rate.
Article in Biochemistry. Biokhimiia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Compensation Effect of Mortality: A Global Analysis of Human Populations.Ageing and longevity research · 2025Article
- Compensation effect of mortality is a challenge to substantial lifespan extension of humans.Biogerontology · 2024Article
- Exploring Patterns of Human Mortality and Aging: A Reliability Theory Viewpoint.Biochemistry. Biokhimiia · 2024Review
- Actuarial Aging Rates in Human Cohorts.Biochemistry. Biokhimiia · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The compensation effect of mortality (CEM) was tested and species-specific lifespan was estimated using data on one-year age-specific death rates from the Human Mortality Database (HMD). CEM was confirmed using this source of the data and human species-specific lifespan estimates were obtained, which were similar to the estimates published before. Three models (Gompertz-Makeham, Gompertz-Makeham with mean-centered age, and Gompertz) produced similar estimates of the species-specific lifespan. These estimates demonstrated some increase over time. Attempts to measure aging rates through the Gompertz slope parameter led to the conclusion that actuarial aging rates were stable during most of the 20th century, but recently demonstrated an increase over time in the majority (74%) of studied populations. This recent phenomenon is most likely caused by more rapid historical decline of mortality at the younger adult age groups compared to the older age groups, thus making the age gradient in mortality steeper over time. There is no biomedical reason to believe that human aging rates accelerated recently, so that the actuarial aging rate is probably not a good measure of true aging rate (rate of functional loss). Therefore, better measures of aging rate need to be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.